Novo Nordisk Collaborates with Evotec to Develop Therapies Targeting Chronic Kidney Disease
Shots:
- Evotec to receive $179M/ product as upfront- research funding and milestones along with the royalties on sales of the therapies while Novo Nordisk will lead the clinical development and commercialization of the therapies
- The companies will share responsibilities during drug discovery and pre-clinical development and will jointly identify and develop novel targets based on medical and molecular data sets of thousands of CKD patients
- The collaboration allows Novo Nordisk to expand its portfolio beyond diabetes targeting the unmet medical needs of patients
Click here to read full press release/ article | Ref: Novo Nordisk | Image: GMP News
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com